| Phase 13 trials |
|
Phase 1
|
NCT07309042 |
Dec 2025 → Feb 2026 overdue |
atherosclerotic cardiovascular disease, cerebrovascular disorder |
Beijing Inno Medicine Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT07190885 |
Nov 2025 → Feb 2026 overdue |
— |
Beijing Inno Medicine Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT05635084 |
Dec 2022 → Aug 2024 |
cardiovascular disorder |
Beijing Inno Medicine Co., Ltd. |
Completed
|
No outcome recorded
|
| Phase 1/21 trial |
|
Phase 1/2
|
NCT06048588 |
Oct 2023 → Apr 2025 |
atherosclerotic cardiovascular disease |
Beijing Inno Medicine Co., Ltd. |
Completed
|
No outcome recorded
|
| Phase 22 trials |
|
Phase 2
|
NCT07521007 |
Jul 2026 → Jul 2027 expected |
atherosclerosis, coronary artery disorder |
Beijing Inno Medicine Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06700720 |
Feb → Jun 2026 overdue |
coronary atherosclerosis |
Beijing Inno Medicine Co., Ltd. |
Recruiting
|
No outcome recorded
|